Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
5
×
life sciences
national blog main
national top stories
new york blog main
5
×
new york top stories
startups
wisconsin blog main
5
×
wisconsin top stories
boston blog main
boston top stories
cancer
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
biotech
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
eli lilly
indiana blog main
indiana top stories
johnson & johnson
national
abbvie
aduro biotech
agenus
alzheimer's disease
biogen
bristol-myers squibb
car-t immunotherapy
What
companies
5
×
bio
drug
roundup
nash
news
price
startup
admits
ago
alzheimer’s
appear
approval
approved
big
biggest
biogen’s
biopharmaceutical
biotechs
classes
combinator
convo
deal
deerfield
didn't
different
digital
disease
dug
earlier
end
epidemic
eyeing
fail
failures
fatty
fda
frenzied
gene
growing
Language
unset
Current search:
companies
×
deals
×
" new york blog main "
×
" wisconsin blog main "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
After Deal Stalled, Shine Medical Eyeing Up to $160M from Deerfield